15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 6 firms covering Xeris Pharmaceuticals Inc, 5 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $8.00 to $18.00 (about 2.3x), a sign of real disagreement on valuation. The average target of $10.80 sits 32% above the current $8.20. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.04 next quarter toward $0.39 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS6 ratings
Moderate Buy
Strong Buy00%
Buy583%
Hold117%
Sell00%
Strong Sell00%
Based on 6 analysts giving stock ratings to Xeris Pharmaceuticals Inc.
As of Jul, 5 of 6 firms rate XERS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
XERS EPS & revenue forecast
EPS · NEXT QUARTER
$0.04
Range $0.03 – $0.05 · 4 analysts
Next period, 4 analysts expect Xeris Pharmaceuticals Inc to earn $0.04 a share (range $0.03 – $0.05), versus $0.00 a year earlier. Full-year consensus is $0.14, growing to $0.39 the year after.
REVENUE · NEXT QUARTER
$100.9M
Range $99.5M – $102.9M · 4 analysts · +36% YoY
Revenue is expected to reach $100.9M (range $99.5M – $102.9M), +35.7% year-over-year. Full-year consensus is $385.9M, rising to $472.4M next year.
Top analysts covering Xeris Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on XERS.
#1
Chase Knickerbocker
Craig-Hallum · Rank #25
Buy
$6.50-20.7% to target
Overall win rate
58%
+ Follow
#2
David Amsellem
Piper Sandler · Rank #95
Hold
$8.00-2.4% to target
Overall win rate
50%
+ Follow
#3
Oren Livnat
HC Wainwright & Co. · Rank #142
Buy
$8.00-2.4% to target
Overall win rate
54%
+ Follow
#4
Leland Gershell
Oppenheimer · Rank #254
Buy
$18.00+119.5% to target
Overall win rate
37%
+ Follow
#5
BF
Brandon Folkes
HC Wainwright & Co.
Buy
$10.00+22.0% to target
Coverage
—
+ Follow
XERS stock forecast FAQ
What is XERS's average 12-month price target?+
The 5 analysts with a live target average $10.80 for Xeris Pharmaceuticals Inc over the next 12 months, ranging from a $18.00 high to a $8.00 low.
Is XERS stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 6 analyst ratings, 5 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for XERS?+
The Street-high target is $18.00 (Oppenheimer), and the Street-low is $8.00 (Piper Sandler). The average of all 5 active targets is $10.80.
How many Wall Street analysts cover XERS?+
6 analysts have an active rating on Xeris Pharmaceuticals Inc, and 5 firms carry a live 12-month price target.
Who is the most accurate analyst covering XERS?+
Among analysts who currently cover XERS, Chase Knickerbocker of Craig-Hallum has the strongest overall Quantellect track record (Rank #25). Their current call is Buy with a $6.50 target.
What is Xeris Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.04 per share (range $0.03 – $0.05) across 4 analysts. Full-year EPS is projected at $0.14, rising to $0.39 the following year.
How much revenue is Xeris Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $100.9M (range $99.5M – $102.9M). Full-year revenue is projected at $385.9M, growing to $472.4M next year.
Have analysts been upgrading or downgrading XERS lately?+
As of Jul, 5 of 6 firms rate XERS a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their XERS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
